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A simple, rapid and reproducible HPLC method was developed for the simultaneous determination of 
amlodipine and valsartan in their combined dosage forms, and for drug dissolution studies. A C18 column 
(ODS 2, 10 µm, 200 x 4.6 mm) and a mobile phase of phosphate buffer (pH 3.6 , 0.01 mol L-1):acetonitrile: 
methanol (46:44:10 v/v/v) mixture were used for separation and quantification. Analyses were run at a 
flow-rate of 1 mL min-1 and at ambient temperature. The injection volume was 20 µL and the ultraviolet 
detector was set at 240 nm. Under these conditions, amlodipine and valsartan were eluted at 7.1 min 
and 3.4 min, respectively. Total run time was shorter than 9 min. The developed method was validated 
according to the literature and found to be linear within the range 0.1 – 50 µg mL-1 for amlodipine, and 
0.05 – 50 µg mL-1 for valsartan. The developed method was applied successfully for quality control 
assay of amlodipine and valsartan in their combination drug product and in vitro dissolution studies.
Uniterms: Amlodipine besylate. Valsartan. High Performance Liquid Chromatography. Method 
Development. Validation. Dissolution Study.
Desenvolveu-se método de HPLC rápido e reprodutível para a determinação simultânea de anlodipino 
e valsartana em suas formas de associação e para os estudos de dissolução dos fármacos. Utilizaram-se 
coluna C18 (ODS 2, 10 µm, 200 x 4,6 mm) e fase móvel tampão fosfato (pH 3,6, 0,01 mol L-1):acetonitrila: 
metanol para a separação e a quantificação. As análises foram efetuadas com velocidade de fluxo de 1 mL 
min-1 e à temparatura ambiente O volume de injeção foi de 20 µL e utilizou-se detector de ultravioleta a 
240 nm. Sob essas condições, anlodipino e valsartana foram eluídas a 7,1 min e 3,4 min, respectivamente. 
O tempo total de corrida foi menor que 9 min. O método desenvolvido foi validado de acordo com a 
literatura e se mostrou linear na faixa de 0,1-50 µg mL-1 para anlodipino e de 0,05-50 µg mL-1  para 
valsartana. O método desenvolvido foi aplicado com sucesso para ensaios de controle de qualidade de 
associações de anlodipino e valsartana e nos estudos de dissolução in vitro.
Uniterms: Anlodipino/determinação. Valsartana/determinação. Cromatografia líquida de alta eficiência/
análise quantitativa. Fármacos/dissolução in vitro.
INTRODUCTION
Amlodipine (as besylate, mesylate or maleate) is a 
long-acting calcium channel blocker used as an anti-hyper-
tensive agent and in the treatment of angina (Haria, Wag-
staff, 1995; Murdoch, Heel, 1991). Akin to other calcium 
channel blockers, amlodipine (AMD) acts by relaxing the 
smooth muscle in the arterial wall, decreasing peripheral 
resistance and hence reducing blood pressure. In angina 
it increases blood flow to the heart muscle. Valsartan 
(VAL) is an angiotensin II receptor antagonist, acting on 
the AT1 subtype (Markham, Goa, 1997; Remuzzi et al., 
1998). VAL keeps blood vessels from narrowing, which 
lowers blood pressure and improves blood flow. VAL is 
used to treat hypertension. It is sometimes given together 
with other blood pressure medications. It was noted that 
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the combination of an angiotensin receptor blocker and a 
calcium channel blocker constitutes an effective option 
for patients with hypertension (Boutouvrie et al., 2008; 
Plosker, Robinson, 2008)
In the literature, several HPLC methods have been 
described for the determination of AMD in pharmaceutical 
preparations when used alone (Avadhanulu et al., 1996; Ba-
savaiah et al., 2005; Fang et al., 2007; Kamat, Chaturvedi, 
2005; Li et al., 2006; Patki et al., 1994; Shang, Shang, 1996; 
Ustun, Atay, 2006; Xiao, Wang, 2007) or in combination 
with other compounds such as atorvastatin, atenolol, bena-
zepril, losartan, ramipril and enarapril maleate (Aravindraju 
et al., 2006; Barman et al., 2007; Dhorda, Shetkar, 1999; 
Dongre et al., 2008; Freddy, Chaudhari, 2005; Gowri et al., 
2002; Halkar et al., 1998; Luksa et al., 1997; Mohammadi 
et al., 2007; Rajeswari et al., 2006; Rajkondawar, 2006; 
Rao et al., 2002; Sankar et al., 1997; Shah et al., 2006; Si-
vakumar et al., 2007; Zarapkar, Kanyawar, 2002; Zarapkar 
et al., 1997). HPLC methods for the determination of VAL 
in pharmaceutical preparations have also been described 
(Carlucci et al., 2000; Doshi et al., 2008; Han et al., 2007; 
Jin et al., 2006; Satana et al., 2001; Tatar, Saglik, 2002).
There is an HPLC method described for simultane-
ous determination of AMD and VAL (Figure 1) in pharma-
ceutical preparations (Chitlange et al., 2008). In addition, 
there is another method reported for simultaneous determi-
nation of these drugs for liver perfusion studies (Celebier 
et al., 2008) However, both methods are not developed for 
dissolution studies while the dissolution profile of AMD 
and VAL from the combination drug product has not hith-
erto been reported in the literature. In order to elucidate the 
dissolution profiles of AMD and VAL, a validated HPLC 
method is required for simultaneous determination of these 
drugs in dissolution matrix.
Therefore, the aim of this study was to develop 
and validate an efficient HPLC method for simultaneous 
determination of AMD and VAL and to introduce the 
dissolution profiles of these drugs. Moreover, this new 
method could also be used for the routine analysis of AMD 
and VAL in pharmaceutical dosage forms, provided it is 
completely validated and rapid. The newly developed 
method was totally different both in terms of methodology 
and aim in comparison to previously reported methods in 
the literature.
The method was validated according to guidelines 
(Thompson et al., 2002) and applied for assay of AMD and 
VAL from their combination tablet dosage form. Also, in 
vitro dissolution of AMD and VAL containing tablets were 
performed to validate the suitability of the proposed method.
MATERIAL AND METHODS
Chemicals
Standard AMD and VAL were supplied by Refik 
Saydam National Public Health Agency. Methanol and 
acetonitrile were of HPLC grade from Merck (Darmstadt, 
Germany) and all other reagents were analytical grade. 
Water obtained from the Milli-Q water system (Barns-
tead, USA) was used for the preparation of buffer and 
other aqueous solutions. Commercially available tablets 
(Exforge®) containing 5 mg of AMD (as equal to 6.94 mg 
of AMD besylate) and 160 mg of VAL were purchased 
from a local pharmacy.
Solutions
Standard stock solutions
Standard stock solutions of AMD and VAL were 
prepared separately by dissolving 50 µg of AMD besylate 
and 50 mg of VAL in 50 mL methanol, and stored protec-
ted from daylight at 4oC until use. These solutions were 
prepared freshly every week, during method development 
and application period.
Phosphate buffer solution
1.74 g of K2HPO4 was dissolved in 1 L of deionized 
water and pH was adjusted to 3.6 with orthophosphoric acid.
Calibration standards
Calibration standards for AMD (as besylate salt) 
and VAL (1.25, 2.0, 3.0, 4.0, 10.0, 20.0, 30.0, 40 and 
50.0 µg mL-1) were daily prepared from standard stock 
solutions by appropriate dilution processes using mobile 
phase.
Instrumentation
The HPLC system consisted of a Waters 2690 Sepa-
ration Module equipped with a Waters 2996 Photodiode 
FIGURE 1 - The chemical structures of amlodipine besylate 
and valsartan.
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Array Detector (Waters, USA). A C18 column (Waters 
Spherisorp (PSS832514) ODS 2, 10 µm, 200 x 4.6 mm; 
USA) was used for separation and quantification. The 
mobile phase consisted of phosphate buffer (pH 3.6 , 
0.01 mol L-1): acetonitrile : methanol (46:44:10 v/v/v) and 
was filtered through a 0.45 µm filter and degassed before 
use. The injection volume was 20 µL and the ultraviolet 
detector was set at 240 nm. Analyses were run at a flow-
rate of 1 mL min-1 at an ambient temperature (25 oC). The 
peak areas were integrated automatically by using Em-
power® software. Under these conditions, VAL and AMD 
were eluted at 3.4 min and 7.1 min, respectively. Total run 
time was shorter than 9 min.
In vitro dissolution studies
In vitro dissolution of six tablets containing AMD and 
VAL was performed using phosphate buffer (pH 6.8) as the 
dissolution media at 50 rpm using an USP Apparatus II. The 
dissolution study was carried out in a 900 mL volume of 
phosphate buffer at 37 °C (± 0.5) using the paddle method. 
One mL of sample was withdrawn and replaced with fresh 
dissolution medium at the time intervals of 0, 5, 10, 15, 20, 
30, 45, and 60 minutes. The sample (250 µL) was diluted with 
mobile phase (750 µL) and then filtered through a 0.45 µm 
membrane filter. The concentrations of AMD and VAL in 
samples were determined by the proposed HPLC method.
According to the FDA Guidance (Qui, Xu 2007) no 
less than 85% of the active ingredients of the labeled claim 
should be dissolved within 30 minutes.
Analysis of dosage forms
Ten tablets were weighed to determine their mean 
weight, and finely powdered in a mortar. An amount of 
powdered mass equivalent to one tablet was accurately wei-
ghed and transferred to a 100 mL volumetric flask. A 50 mL 
volume of methanol was added then sonicated for 15 min to 
ensure complete extraction of the drugs. The flask was then 
diluted to volume with methanol. An aliquot from this solu-
tion was centrifuged at 5000 rpm for 10 min. Clear superna-
tant was transferred to another flask. Appropriate aliquots 
from the sample solution were suitably diluted with mobile 
phase so as to achieve concentrations of 1.25 µg mL-1 and 
40.0 µg mL-1 for AMD and VAL, respectively. Twenty µL 
of this solution was injected into the HPLC system after 
filtration through a 0.45 µm membrane filter.
Synthetic tablet solutions
For preparation of the synthetic tablets, common 
inactive ingredients (microcrystalline cellulose, povidone, 
talc, magnesium stearate, starch, iron oxide) and standard 
AMD besylate (6.94 mg) and VAL (160 mg) at amounts 
equivalent to one tablet were weighed and transferred to 
a 50 mL volumetric flask. The same procedure described 
in Section 2.5 was then applied to prepare the synthetic 
tablet solutions containing 1.25 µg mL-1 of AMD and 
40.0 µg mL-1 of VAL, respectively. In order to prepare 
blank tablet solutions, the synthetic tablet solutions were 
prepared in the absence of AMD and VAL.
RESULTS AND DISCUSSION
Method optimization
Due to the relatively apolar properties of AMD and 
VAL, a reversed phase HPLC system was used to analyze 
both compounds with a sufficient separation and fine 
peak shapes within a short analysis time. Therefore, all 
the experiments were carried out on a C18 column (Waters 
Spherisorp ODS 2, 10 µm, 200 x 4.6 mm) by trying various 
mobile phase conditions systematically. After the initial 
experiments, the optimum conditions were found to be the 
mobile phase of phosphate buffer (pH 3.6, 0.01 mol L-1): 
acetonitrile: methanol (46:44:10 v/v/v) mixture pumped at 
1 mL min-1 flow rate and 240 nm UV detection wavelength. 
Under the optimum conditions, VAL and AMD were eluted 
at 3.4 min and 7.1 min, respectively.
System suitability
A suitability test was applied to the chromatograms 
taken under optimum conditions to check various para-
meters such as column efficiency (plates), peak tailing, 
retention factor, and resolution. Suitable resolution (>2) 
and column efficiency (>1500 for both compounds) were 
achieved for the analysis method. The peak symmetries 
for both compounds were <1.2 , whereas the capacity 
factors were >1.5 . The analysis time was shorter than 
9 minutes.
Method validation
The proposed method was validated as to linearity 
range, sensitivity, repeatability, precision, accuracy, and 
specificity according to the literature (Ermer, 2001; Ermer, 
Ploss, 2005; Taverniers et al., 2004a; Taverniers et al., 
2004b; Thompson et al., 2006).
Linearity range
The solutions of AMD and VAL at different con-
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centrations were analyzed. According to the observations, 
the peak shapes worsened after 50 µg ml-1 for both com-
pounds. The graph of the peak area against concentration 
proved linear up to 50 µg mL-1 . Therefore, eight different 
concentrations of AMD and VAL within the linear range 
were analyzed. This process was repeated six times to 
calculate the regression equations. The results are given 
in Table I.
Limit of detection (LOD) and limit of quantitation (LOQ)
The signal-to-noise ratios of 3:1 and 10:1 were taken 
as LOD and LOQ, respectively (Taverniers et al., 2004a; 
Taverniers et al., 2004b). The values of LOD and LOQ for 
both AMD and VAL are given in Table I.
Repeatability
The repeatability of the developed HPLC method 
was calculated by 10 consecutive injections made with 
standard solutions containing 20.00 μg mL−1 of AMD 
and VAL. The results were evaluated by considering re-
tention time and peak area. Neither the peak areas, nor the 
retention time changed more than 2 %, indicating that the 
method was highly repeatable.
Precision and accuracy
Three different concentrations of standard AMD 
and VAL solutions (within the linear range) were analyzed 
on three consecutive days (inter-day precision) and three 
times within the same day (intra-day precision). The obtai-
ned values for relative standard deviation (RSD) and Bias 
of intra- and inter-day studies indicated that the precision 
and accuracy of the method were satisfactory (Taverniers, 
et al. 2004a; Taverniers, et al. 2004b). The results are 
summarized in Table II.
Recovery
To verify the accuracy of the method, recovery 
experiments were performed. The synthetic tablets and 
synthetic tablet solutions were analyzed by the developed 
method. The results were 98.5 ± 0.8 and 99.6 ± 0.6 (mean 
± SE where SE is standard error) for AMD and VAL, 
respectively.
Selectivity
The chromatograms obtained from standard solu-
tions were identical to those obtained from tablet solutions 
containing an equivalent concentration of AMD and VAL. 
TABLE I - Linearity data of the developed method (n=6)
AMD besylate VAL
Regression equation* y = 39604 x + 2682 y = 42497 x + 12845
Standard error of intercept 308 99
Standard error of slope 758 761
Correlation coefficient (r) 0,9992 0,9991
Linearity range (µg.mL-1) 0.1 - 50 0.05 - 50
Number of data points 8 8
LOD (µg.mL-1) 0.05 0.02
LOQ (µg.mL-1) 0.1 0.05
*where y is peak area and x is concentration in µg mL-1
TABLE II - Precision and accuracy of the developed method 
Intra-day Inter-day
Added 
(mg mL-1)
Found 
(mg mL-1)
Precision 
RSD %
Accuracy 
Bias %
Found 
(mg mL-1)
Precision 
RSD %
Accuracy 
Bias %
Amlodipine bes. 3 2.95 ± 0.02 1.5 -3.3 2.86 ± 0.02 2.1 -4.7
20 20.38 ± 0.22 2.6 2.8 20.83 ± 0.08 0.9 5.4
40 39.28 ± 0.30 1.9 -3.2 40.24 ± 0.27 1.6 -1.5
Valsartan 3 2.86 ± 0.03 2.1 -4.7 2.71 ± 0.03 3.6 -6.1
20 20.72 ± 0.18 2.1 4.1 20.58 ± 0.08 0.9 4.2
40 39.84 ± 0.14 0.9 -1.6 40.03 ± 0.27 1.7 -2.0
Found: mean ± standard error (n=6); RSD: Relative standard deviation; Bias: [(Found - Added)/Added] x 100
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The representative chromatograms (Figure 2) show no 
other peaks in retention time of AMD and VAL and reten-
tion times did not change. In addition, when the solution 
prepared from the blank tablet was injected into the HPLC 
system, no co-eluting peaks were obtained at the retention 
time of AMD and VAL.
Based on these results, the proposed methods can be 
considered selective.
Tablet analysis results
The assay results of AMD and VAL in tablet dosage 
form were comparable with the label value claimed (5 mg 
AMD and 160 mg VAL (Exforge®). The results presented 
in Table III indicate the suitability of the method for rou-
tine analysis of AMD and VAL from their combination 
drug products.
In vitro dissolution studies
The average percentage drugs released within 60 
min as detected by the proposed HPLC method after in 
vitro dissolution of tablets containing combination drug 
product are depicted in Figure 3. VAL was completely re-
leased within 10 min, whereas 85% of AMD was released 
within 15 min. The dissolution pattern complies with the 
FDA Guidance (Qui and Xu 2007) standards, indicating 
suitability of the proposed method for the dissolution study 
of the two drugs.
CONCLUSION
It is a well known that validation procedure is an 
integral part of the analytical method development. The-
refore, the developed method was validated according to 
the guidelines. Based on the results, it can be concluded 
that there is no other co-eluting peak with the main peaks 
and that the method is specific for estimation of AMD and 
VAL. The proposed method has linear response in the sta-
ted range and is accurate and precise. To our knowledge, 
the developed HPLC method is the first reported method 
for simultaneous determination of AMD and VAL from 
their combination drug product. Taken together, these re-
sults clearly showed that this method can be used for assay 
of AMD and VAL in their combination drug product. The 
developed method can also be conveniently adopted for 
dissolution testing of tablets containing AMD and VAL.
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